93 related articles for article (PubMed ID: 16899786)
21. Irreversible sensorineural hearing loss due to Imatinib.
Attili VS; Bapsy PP; Anupama G; Lokanatha D
Leuk Res; 2008 Jun; 32(6):991-2. PubMed ID: 18221994
[TBL] [Abstract][Full Text] [Related]
22. [Porphyria cutanea tarda in a patient presenting hepatitis C treated with imatinib].
Chraïbi R; Labeille B; Perrot JL; Cambazard F
Ann Dermatol Venereol; 2008 Nov; 135(11):775-6. PubMed ID: 19061660
[No Abstract] [Full Text] [Related]
23. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
24. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
Michael M; Antoniades M; Lemesiou E; Papaminas N; Melanthiou F
Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
[TBL] [Abstract][Full Text] [Related]
25. [Glivec induced autoimmune hepatitis].
Charier F; Chagneau-Derrode C; Levillain P; Guilhot F; Silvain C
Gastroenterol Clin Biol; 2009; 33(10-11):982-4. PubMed ID: 19765927
[No Abstract] [Full Text] [Related]
26. Imatinib-induced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor.
Battistella M; Frémont G; Vignon-Pennamen MD; Gornet JM; Dubertret L; Viguier M
Arch Dermatol; 2008 Oct; 144(10):1400-2. PubMed ID: 18936416
[No Abstract] [Full Text] [Related]
27. Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Chang H; Shih LY
Chang Gung Med J; 2008; 31(5):510-4. PubMed ID: 19097599
[TBL] [Abstract][Full Text] [Related]
28. Sensorineural hearing loss following imatinib (Gleevec) administration.
Lin HW; Roberts DS; Kay J; Stankovic KM
Otolaryngol Head Neck Surg; 2012 Feb; 146(2):335-7. PubMed ID: 21753034
[No Abstract] [Full Text] [Related]
29. Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
Busuttil DP
Int J Lab Hematol; 2008 Feb; 30(1):68-70. PubMed ID: 18190471
[TBL] [Abstract][Full Text] [Related]
30. Paraneoplastic insulin resistance syndrome in advanced aggressive fibromatosis (desmoid tumor) treated by imatinib mesylate.
Folli F; Galimberti G; Pastore M; Davalli AM; Bosi E
Diabetes Care; 2006 Sep; 29(9):2178-80. PubMed ID: 16936177
[No Abstract] [Full Text] [Related]
31. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Al-Kali A; Farooq S; Tfayli A
J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
[TBL] [Abstract][Full Text] [Related]
32. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
Breccia M; Alimena G
Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
[TBL] [Abstract][Full Text] [Related]
33. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
34. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.
Foringer JR; Verani RR; Tjia VM; Finkel KW; Samuels JA; Guntupalli JS
Ann Pharmacother; 2005 Dec; 39(12):2136-8. PubMed ID: 16288076
[TBL] [Abstract][Full Text] [Related]
35. Imatinib: new indication. New indications, but not robust evidence.
Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Scheinfeld N
J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
[TBL] [Abstract][Full Text] [Related]
37. Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care.
Keefe D; Anthony L
Curr Opin Support Palliat Care; 2008 Mar; 2(1):19-21. PubMed ID: 18685389
[No Abstract] [Full Text] [Related]
38. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
Antoniu SA
Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
[TBL] [Abstract][Full Text] [Related]
39. Syndrome of inappropriate secretion of antidiuretic hormone associated with imatinib.
Liapis K; Apostolidis J; Charitaki E; Panitsas F; Harhalakis N; Nikiforakis E
Ann Pharmacother; 2008 Dec; 42(12):1882-6. PubMed ID: 19017824
[TBL] [Abstract][Full Text] [Related]
40. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.
Porta C; Mutti L; Tassi G
Cancer Chemother Pharmacol; 2007 Jan; 59(1):149-50. PubMed ID: 16636799
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
